<?xml version='1.0' encoding='utf-8'?>
<document id="23016456"><sentence text="Tacrolimus strongly inhibits multiple human UDP-glucuronosyltransferase (UGT) isoforms." /><sentence text="The objective of the present study is to clearly evaluate the inhibitory effects of tacrolimus (tacro) on important UGT isoforms in human liver, including determination of inhibition kinetic type and calculation of inhibition kinetic parameters"><entity charOffset="84-94" id="DDI-PubMed.23016456.s2.e0" text="tacrolimus" /><entity charOffset="96-101" id="DDI-PubMed.23016456.s2.e1" text="tacro" /><pair ddi="false" e1="DDI-PubMed.23016456.s2.e0" e2="DDI-PubMed.23016456.s2.e0" /><pair ddi="false" e1="DDI-PubMed.23016456.s2.e0" e2="DDI-PubMed.23016456.s2.e1" /></sentence><sentence text=" An in vitro incubation system was used to investigate the inhibitory effect of tacro on UGT isoforms"><entity charOffset="80-84" id="DDI-PubMed.23016456.s3.e0" text="tacro" /></sentence><sentence text=" The recombinant UGT isoforms were used as enzyme source, and a nonspecific substrate 4-methylumbelliferone (4-MU) was utilized as substrate"><entity charOffset="86-107" id="DDI-PubMed.23016456.s4.e0" text="4-methylumbelliferone" /><entity charOffset="109-113" id="DDI-PubMed.23016456.s4.e1" text="4-MU" /><pair ddi="false" e1="DDI-PubMed.23016456.s4.e0" e2="DDI-PubMed.23016456.s4.e0" /><pair ddi="false" e1="DDI-PubMed.23016456.s4.e0" e2="DDI-PubMed.23016456.s4.e1" /></sentence><sentence text=" Among the tested UGT isoforms, UGT1A1, UGT1A3, UGT2B7 and UGT2B15 were strongly inhibited by tacro in a concentration-dependent manner"><entity charOffset="94-97" id="DDI-PubMed.23016456.s5.e0" text="tacro" /></sentence><sentence text=" Dixon and Lineweaver-Burk plots showed that the inhibition of UGT1A1, UGT1A3, and UGT2B7 was all best fit to competitive inhibition type, and the inhibition of UGT2B15 was best fit to noncompetitive type" /><sentence text=" The inhibition kinetic parameters (Ki) were determined to be 4" /><sentence text="7, 1" /><sentence text="3, 1" /><sentence text="9, and 4" /><sentence text="3 microM for UGT1A1, UGT1A3, UGT2B7, and UGT2B15, respectively" /><sentence text=" Inhibition of these important UGT isoforms in human liver might be an important reason for clinically frequent drug-drug interaction between tacro and other drugs"><entity charOffset="142-146" id="DDI-PubMed.23016456.s12.e0" text="tacro" /></sentence><sentence text="" /></document>